ACC 2021 | Emergent CABG for acute MI: Benefits Despite Risk

The latest figures show a lower number of emergency CABG for acute MI, and in turn increased primary PCI. 

ACC 2021 | Cirugía de emergencia en el infarto: beneficios a pesar del alto riesgo

The combination of surgeons not willing to take risks and interventional cardiologists empowered to treat practically any lesion has resulted in fewer patients receiving emergency CABG. Only a few years ago, interventional cardiologists at least had the “courtesy” to agree on a treatment strategy with the surgeon on call. Several years of choosing PCI over CABG have granted interventionists clearance to bypass surgeons and directly proceed to percutaneous intervention, practically in every center. 

This study presented today at ACC 2021 simultaneously published in JAHA, shows the figures behind the above statements. Comparing the years 2000 and 2017, emergency CABG saw a 90% reduction. 

It is also clear that surgical techniques and post operatory care have improved in the same period. This has contributed to keep a clear benefit in terms of mortality, despite volume reduction and case selection. 

When comparing patients undergoing surgery in the first part of the study vs the second part, some interesting information becomes clear


Read also: ACC 2021 | LAAOS III: Appendage Closure During Central Vascular Surgery.


Patients treated in the second, most recent period, were more frequently non-STEMI cases (80.5% vs 56.1%), more often presented non-cardiac multiorgan failure (26.1% vs 8.4%), presented cardiogenic shock (11.5% vs 6.4%) and received mechanical circulatory support (19.8% vs 18.7%; p< 0.001 for all comparisons). 

Despite all the above mentioned, mortality in these periods resulted similar (5.3% in 2000 vs 3.6% in 2017).

Original Title: Temporal trends, clinical characteristics and outcomes of emergent coronary artery bypass grafting for acute myocardial infarction in the United States.

Reference: Patlolla SH et al. Presentado en el congreso de la ACC 2021 y publicado simultáneamente en J Am Heart Assoc.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....